Why exosome supplier due diligence looks different from tissue allografts
FDA has stated that there are no FDA-approved exosome products. Extracellular vesicle and exosome preparations are generally regulated as biologic drugs under section 351 of the Public Health Service Act, a different pathway than the section 361 framework that may apply to a given tissue allograft depending on its specific intended use. Purchase and clinical-use decisions for these products belong to the physician, together with their own regulatory counsel.
That distinction changes what due diligence should look like. Instead of asking only about donor screening, a buyer evaluating an exosome supplier needs to ask about analytical characterization, source material, and how the supplier describes its own regulatory status, since no exosome product currently carries FDA approval or clearance.
The list below groups 14 documents into four categories: characterization, source and manufacturing, regulatory, and commercial support.
Characterization documents (1-5)
Ask for the analytical data that establishes what is actually in the vial, not just the marketing description of it. The 2023 minimal information guidance for extracellular vesicle studies recommends reporting source, size, concentration, and marker data, and recommends using the term "extracellular vesicles" unless exosome biogenesis has specifically been demonstrated.
- 1. Certificate of analysis for the specific lot
- 2. Particle concentration report (nanoparticle tracking analysis)
- 3. Characterization report covering ELISA and single particle interferometric reflectance imaging sensing (SP-IRIS)
- 4. Tetraspanin marker identification data (such as CD81 and CD9)
- 5. Growth factor and cytokine panel data sheet, presented as analytical findings, not as a statement of effect
Source and manufacturing documents (6-9)
Ask where the particles come from. If a product is derived from a defined progenitor cell line rather than from a specific tissue donor, request documentation for that source cell line in place of per-donor records, and ask what quality testing accompanies release of each lot.
- 6. Source cell line documentation (e.g., progenitor endothelial cell line origin)
- 7. Sterility testing report
- 8. Endotoxin and bioburden testing report
- 9. Lot quarantine and release record
Regulatory and legal documents (10-12)
FDA has sent warning letters to distributors in this category for making disease claims on websites and social media, and FDA reads a distributor's own marketing and affiliate content as evidence of a product's intended use. A "research use only" label does not change that analysis if a product is being promoted for clinical use elsewhere. This section is general information, not legal advice, and any supplier's written regulatory position should be reviewed by your own FDA regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information in this checklist is for licensed healthcare professionals and is not medical or legal advice.
- 10. Written statement of the supplier's regulatory position and section 351 disclosure
- 11. Documentation supporting any registration or licensure claim, available for you to verify directly
- 12. Full ingredient disclosure for any formulated product (added peptides, excipients)
Commercial and support documents (13-14)
The last two items are about how the supplier operates day to day, not about the product itself. Confirm that account access requires verification through an NPI number, and ask whether the supplier offers access to physician-level conversations about documentation, which is different from clinical or dosing advice and should be presented that way.
- 13. Account verification policy tied to NPI confirmation
- 14. Availability of physician-level documentation support (not clinical or dosing guidance)
How to use this checklist when comparing suppliers
Request all 14 items in writing before opening an account. A supplier missing characterization data cannot show what is in the vial; a supplier missing regulatory disclosures cannot show what framework applies to its product.
Frequently asked questions
Are exosome products regulated the same way as Wharton's jelly allografts?+
No. Exosome and extracellular vesicle preparations are generally regulated as biologic drugs under section 351, a different framework than the section 361 pathway that may apply to a given tissue allograft depending on its intended use. FDA has stated there are no FDA-approved exosome products, and purchase and clinical-use decisions for these products belong to the physician and their own regulatory counsel.
Does a "research use only" label protect a clinic that uses an exosome product clinically?+
No. FDA has indicated that a research-use-only label does not change its analysis of intended use if a product is promoted for clinical application elsewhere, including on a distributor's own marketing or affiliate content.
What does the CD81/CD9 marker data actually tell a buyer?+
It is characterization data identifying tetraspanin markers associated with extracellular vesicles. Present it as an analytical finding about composition, not as evidence of a clinical effect.
Who should review a supplier's regulatory disclosures before we rely on them?+
Your clinic's own FDA regulatory counsel. This checklist helps you gather the right documents; it does not substitute for a legal review of what they mean for your intended use.